文献速递肿瘤 PET/CT

68Ga-EMP-100 PET/CT:靶向c-MET的转移性肾细胞癌首例人体分布与显像

68Ga-EMP-100 PET/CT-a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma-first in-human biodistribution and imaging results.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-10-28

68Ga-EMP-100是靶向c-MET的新型PET示踪剂。

要点

  • 68Ga-EMP-100 PET/CT可无创显示转移性肾细胞癌的c-MET表达。
  • 87个病灶中79.3%为c-MET阳性,中位SUVmax 4.35。
  • 原发灶摄取最高,肺和肝转移灶多阴性,异质性明显。

核心结论

  • 68Ga-EMP-100靶向c-MET在转移性肾细胞癌患者中显示明显摄取,但存在部分高个体内和个体间差异,包含c-MET阳性和阴性病灶,首临床结果值得进一步系统研究其作为生物标志物的临床用途。

主要发现

  • 共分析87个肿瘤病灶,68/87(79.3%)视觉判读为c-MET阳性,中位SUVmax为4.35,中位SUVmean为2.52。
  • 原发灶肿瘤负荷摄取最高(SUVmax 9.05(4.86-29.16)),其次为骨转移(SUVmax 5.56(0.97-15.85))、淋巴结转移(SUVmax 3.90(2.13-6.28))和内脏转移(SUVmax 3.82(0.11-16.18))。
  • 视觉PET阴性病灶(20.7%)在个体内和个体间分布异质,肺和肝转移中PET阴性病灶比例最大。
  • 除膀胱尿液外,生理性68Ga-EMP-100摄取最高在肾脏,其次为肝脏和脾脏中度摄取,胰腺和肠道摄取强度显著较低。

临床怎么用

  • 68Ga-EMP-100 PET/CT有望在系统治疗前无创评估转移性肾细胞癌的c-MET表达状态,辅助患者管理,但需进一步系统研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 68Ga-EMP-100 is a novel positron emission tomography (PET) ligand that directly targets tumoral c-MET expression. Upregulation of the receptor tyrosin kinase c-MET in renal cell carcinoma (RCC) is correlated with overall survival in metastatic disease (mRCC). Clinicopathological staging of c-MET expression could improve patient management prior to systemic therapy with for instance inhibitors targeting c-MET such as cabozantinib. We present the first in-human data of 68Ga-EMP-100 in mRCC patients evaluating uptake characteristics in metastases and primary RCC. METHODS: Twelve patients with mRCC prior to anticipated cabozantinib therapy underwent 68Ga-EMP-100 PET/CT imaging. We compared the biodistribution in normal organs and tumor uptake of mRCC lesions by standard uptake value (SUVmean) and SUVmax measurements. Additionally, metastatic sites on PET were compared to contrast-enhanced computed tomography (CT) and the respective, quantitative PET parameters were assessed and then compared inter- and intra-individually. RESULTS: Overall, 87 tumor lesions were analyzed. Of these, 68/87 (79.3%) were visually rated c-MET-positive comprising a median SUVmax of 4.35 and SUVmean of 2.52. Comparing different tumor sites, the highest uptake intensity was found in tumor burden at the primary site (SUVmax 9.05 (4.86-29.16)), followed by bone metastases (SUVmax 5.56 (0.97-15.85)), and lymph node metastases (SUVmax 3.90 (2.13-6.28)) and visceral metastases (SUVmax 3.82 (0.11-16.18)). The occurrence of visually PET-negative lesions (20.7%) was distributed heterogeneously on an intra- and inter-individual level; the largest proportion of PET-negative metastatic lesions were lung and liver metastases. The highest physiological 68Ga-EMP-100 accumulation besides the urinary bladder content was seen in the kidneys, followed by moderate uptake in the liver and the spleen, whereas significantly lower uptake intensity was observed in the pancreas and the intestines. CONCLUSION: Targeting c-MET expression, 68Ga-EMP-100 shows distinctly elevated uptake in mRCC patients with partially high inter- and intra-individual differences comprising both c-MET-positive and c-MET-negative lesions. Our first clinical results warrant further systemic studies investigating the clinical use of 68Ga-EMP-100 as a biomarker in mRCC patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Mittlmeier LM, Todica A, Gildehaus FJ, et al. 68Ga-EMP-100 PET/CT-a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma-first in-human biodistribution and imaging results. Eur J Nucl Med Mol Imaging. 2021. PMID: 34708249. doi:10.1007/s00259-021-05596-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。